(Q38118780)

29 August 2017

title

Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma (English)

1 reference

29 August 2017

0 references

Hiroki Nishikawa

1

1 reference

29 August 2017

Yukio Osaki

series ordinal

2

1 reference

29 August 2017

publication date

15 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

44

1 reference

29 August 2017

issue

2

1 reference

29 August 2017

page(s)

149-158

1 reference

Branched-chain amino acids as a protein- and energy-source in liver cirrhosis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Prognostic value of energy metabolism in patients with viral liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Daily energy and substrate metabolism in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Epidemiology of viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Branched-chain amino acids as pharmacological nutrients in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Restoration of innate host defense responses by oral supplementation of branched-chain amino acids in decompensated cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Oral supplementation of branched-chain amino acids reduces early recurrence after hepatic resection in patients with hepatocellular carcinoma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

ESPEN Guidelines on Enteral Nutrition: Liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Factors associated with poor health-related quality of life of patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Disruption of sleep architecture in minimal hepatic encephalopathy and ghrelin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

The surgical approach to HCC: our progress and results in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Hepatocellular carcinoma: current management and perspectives for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Hepatic resection can provide long-term survival of patients with non-early-stage hepatocellular carcinoma: extending the indication for resection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

New therapeutic paradigm for patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Living donor liver transplantation: present status and recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12194

21 January 2018

Identifiers

DOI

10.1111/HEPR.12194

1 reference

29 August 2017

1 reference